Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2664-2668

  Been Tiktak, Anne Mieke M ^a,b   Williams, Ian ^c   Vrehen, Henk M ^a   Richens, John ^c   Aldam, Diana ^c   Van Loon, Anton M ^b,d   Loveday, Clive ^e   Boucher, Charles A B ^b   Ward, Penelope ^f   Weller, Ian V D ^c   Borleffs, Jan C C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEVIRDINE; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; NYSTATIN; PENTAMIDINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; TERBINAFINE;

ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA;

EID: 10344253266     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2664     Document Type: Article

References (22)

1. Been-Tiktak, A. M. M., H. M. Vrehen, M. M. E. Schneider, M. van der Feltz, T. Branger, P. Ward, S. R. Cox, J. D. Harry, and J. C. C. Borleffs. 1995. Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:602-607.
2. Brew, J. B., N. Dunbar, J. Druett, J. Freund, and P. Ward. 1992. Pilot study of the efficacy of atevirdine in AIDS dementia complex. AIDS 8:S532.
3. Campbell, T. B., R. K. Young, J. J. Eron, R. T. D'Aquila, W. G. Tarpley, and D. R. Kuritzkes. 1993. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. J. Infect. Dis. 168:318-326.
4. Centers for Disease Control. 1987. Revision of the CDC surveillance case definition of acquired immunodeficiency syndrome. Morbid. Mortal. Weekly Rep. 36(1S):1-15.
5. Chou, J., and T. C. Chou. 1987. Dose-effect analysis with microcomputers quantification of ED50, LD50, synergism, antagonism, low-dose risk, receptor ligand binding and enzyme kinetics, p. 19-32. A computer software for IBM-PC and manual. Elsevier-Biosoft, Cambridge, United Kingdom.
6. Dueweke, T. J., F. J. Kézdy, G. A. Waszak, M. R. Deibel, Jr., and W. G. Tarpley. 1992. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 267:27-30.
7. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
8. Howard, G. M., and F. J. Schwende. 1993. The development of HPLC-based analytical methods for atevirdine, a novel reverse transcriptase inhibitor for the treatment of AIDS, and associated problems with chromatographic performance, abstr. MP-E12. In Abstracts of the Fourth International Symposium on Pharmaceutical and Biomedical Analysis, 1993.
9. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
10. Loveday, C. 1995. An approach to quantification of serum HIV-1 RNA load by PCR, p. 69-71. In M. R. Haeney (ed.), Proceedings of the National Scientific Meeting of the Association of Clinical Pathologists - 1994.
11. Reichman, R. C., G. D. Morse, L. M. Demeter, L. Resnick, Y. Bassiakos, M. Fischl, M. Para, W. Powderly, J. Leedom, C. Greisberger, and the AIDS Clinical Trials Group 199 Study Team. 1995. Phase 1 study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. J. Infect. Dis. 171: 297-304.
12. Richman, D., C. K. Shin, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
13. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37: 1207-1213.
14. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
15. Romero, D. L., M. Busso, C. K. Tan, F. Reusser, J. R. Palmer, S. M. Poppe, P. A. Aristoff, K. M. Downey, A. G. So, L. Resnick, et al. 1991. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 88: 8806-8810.
16. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, and the L-697,561 Working Group. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
17. Semple, M., C. Loveday, I. Weller, and R. Tedder. 1991. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J. Med. Virol. 35:38-45.
18. Spence, R. A., W. M. Kati, K. S. Anderson, and K. A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
19. Staszewski, S., E. A. Emini, F. Massari, et al. 1993. A double-blind randomized trial for safety, clinical efficacy, biological activity and susceptibility testing in 120 HIV positive patients treated with L-697,661, AZT and combinations of both drugs, abstr. WS-B26-4. In Abstracts of the VIII International Conference on AIDS/III STD World Congress, 1992.
20. Staszewski, S., F. E. Massari, A. Kober, R. Gohler, S. Durr, K. W. Anderson, C. L. Schneider, J. A. Waterbury, K. K. Bakshi, V. I. Taylor, et al. 1995. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J. Infect. Dis. 171:1159-1165.
21. World Medical Association. 1964. Recommendations guiding physicians in biomedical research involving human subjects. In 18th World Medical Assembly. World Medical Association, Geneva. (Abstract. Amended at subsequent meetings in Tokyo [1975], Venice [1983], and Hong Kong [1989]).
22. Yudkin, P. L., and I. M. Stratton. 1996. How to deal with regression to the mean in intervention studies? Lancet 347:241-243.